Platform for antibody discovery
OwnerBarbel Schrofelbauer, Patrick Kimes +1inventors
InventorsBarbel Schrofelbauer, Patrick Kimes, William Hahn
Life of this patent
Estimating the term…
Abstract
The invention is directed to a high throughput platform for the simultaneous discovery of therapeutic antibodies and associated targets based on their phenotypic binding profiles, and monoclonal antibodies discovered therewith.
Claims31
1-7. (canceled)
(canceled)
A method for the sequential selection and identification of an anti-cancer antibody and its target, the method comprising:
- subjecting a phage display input library to affinity selection to produce an output library, wherein affinity selection comprises at least one panning step with a live cell sample positive for a biomarker and at least one panning step with a live cell sample negative for a biomarker;
- selecting from the output library at least one antibody candidate based on sequence analysis, binding profiles, or both;
- synthesizing, manufacturing, or isolating the selected antibody candidate;
- optionally, validating the antibody candidate by flow cytometry;
- and
- identifying the antibody candidate's target by mass spectrometry.
(canceled)
16-19. (canceled)
21-25. (canceled)
27-29. (canceled)
(canceled)
(canceled)
40-42. (canceled)
44-45. (canceled)
A method for identifying a therapeutic target, comprising:
- subjecting an input display library to affinity selection to produce an output library, wherein affinity selection comprises live cell panning;
- analyzing the output library to identify one or more antibodies;
- and
- identifying the target of the one or more antibodies, thereby identifying a therapeutic target and therapeutic antibody.
48-49. (canceled)
Dependencies are inferred from the claim text.